Compare CTM & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTM | DTIL |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5M | 115.5M |
| IPO Year | N/A | 2019 |
| Metric | CTM | DTIL |
|---|---|---|
| Price | $0.96 | $3.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 2.1M | 235.6K |
| Earning Date | 11-07-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,606,863.00 | $698,000.00 |
| Revenue This Year | $23.00 | N/A |
| Revenue Next Year | $11.91 | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.09 | N/A |
| 52 Week Low | $0.61 | $3.61 |
| 52 Week High | $2.19 | $8.82 |
| Indicator | CTM | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 29.42 |
| Support Level | $0.87 | $4.14 |
| Resistance Level | $1.06 | $4.43 |
| Average True Range (ATR) | 0.05 | 0.26 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 27.14 | 1.98 |
Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.